AbbVie eyes cancer, immunology in latest protein degradation pact, handing Frontier Medicines $55M upfront
Two years after tiptoeing into the protein degradation space with a discovery pact centered on neurodegeneration, AbbVie is wading deeper to explore the more common applications in cancer and immunological diseases.
The pharma giant is handing Frontier Medicines $55 million upfront to get things started while promising to reimburse its preclinical R&D costs. In addition to drug candidates that target E3 ligases — a key member of the body’s natural degradation system — Frontier will also be scouting small molecule binders to targets.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.